GSK recalls nearly 600,000 albuterol inhalers

GSK recalls nearly 600,000 albuterol inhalers

British pharmaceuticals giant GlaxoSmithKline (GSK) has announced a voluntary recall for more than 590,000 albuterol inhalers because of a potential issue with their delivery system.

Juan Carlos Molina, a spokesperson for GSK, told reporters that three lots of Ventolin HFA 200D inhalers, with lot numbers 6ZP0003, 6ZP9944 and 6ZP9848, were being recalled due the potential risk.

Confirming the recall, Molina said, “There is possible risk that the affected inhalers could potentially not deliver the stated number of actuations. We continue to investigate the issue in order to identify the root cause and implement appropriate corrective and preventative actions.”

Like any other metered-dose inhalers, albuterol inhalers deliver a fixed dose of medication in the form of aerosol into the body of the patient through the airway and lungs.

An improperly functioning inhaler can release unpredictable, risky dose of medication in the patient’s body.

It isn’t a patient-level recall, but any patient whose inhaler might be among the affected lots can contact the company’s customer service center at 1-888-825-5249. If case of any emergency, patients should immediately seek professional medical treatment.


Share